Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWK679)

Drug Name
OMP-18R5 Drug Info
Synonyms Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMWK679

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Frizzled-7 receptor (FZD7) TTUQMO5 FZD7_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01345201) A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors. U.S. National Institutes of Health.
2 Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22.